Literature DB >> 10817703

Difference in incidence of spontaneous mutations between Herpes simplex virus types 1 and 2.

R T Sarisky1, T T Nguyen, K E Duffy, R J Wittrock, J J Leary.   

Abstract

Spontaneous mutations within the herpes simplex virus (HSV) genome are introduced by errors during DNA replication. Indicative of the inherent mutation rate of HSV DNA replication, heterogeneous HSV populations containing both acyclovir (ACV)-resistant and ACV-sensitive viruses occur naturally in both clinical isolates and laboratory stocks. Wild-type, laboratory-adapted HSV type 1 (HSV-1) strains KOS and Cl101 reportedly accumulate spontaneous ACV-resistant mutations at a frequency of approximately six to eight mutants per 10(4) plaque-forming viruses (U. B. Dasgupta and W. C. Summers, Proc. Natl. Acad. Sci. USA 75:2378-2381, 1978; J. D. Hall, D. M. Coen, B. L. Fisher, M. Weisslitz, S. Randall, R. E. Almy, P. T. Gelep, and P. A. Schaffer, Virology 132:26-37, 1984). Typically, these resistance mutations map to the thymidine kinase (TK) gene and render the virus TK deficient. To examine this process more closely, a plating efficiency assay was used to determine whether the frequencies of naturally occurring mutations in populations of the laboratory strains HSV-1 SC16, HSV-2 SB5, and HSV-2 333 grown in MRC-5 cells were similar when scored for resistance to penciclovir (PCV) and ACV. Our results indicate that (i) HSV mutants resistant to PCV and those resistant to ACV accumulate at approximately equal frequencies during replication in cell culture, (ii) the spontaneous mutation frequency for the HSV-1 strain SC16 is similar to that previously reported for HSV-1 laboratory strains KOS and Cl101, and (iii) spontaneous mutations in the laboratory HSV-2 strains examined were 9- to 16-fold more frequent than those in the HSV-1 strain SC16. These observations were confirmed and extended for a group of eight clinical isolates in which the HSV-2 mutation frequency was approximately 30 times higher than that for HSV-1 isolates. In conclusion, our results indicate that the frequencies of naturally occurring, or spontaneous, HSV mutants resistant to PCV and those resistant to ACV are similar. However, HSV-2 strains may have a greater propensity to generate drug-resistant mutants than do HSV-1 strains.

Entities:  

Mesh:

Year:  2000        PMID: 10817703      PMCID: PMC89907          DOI: 10.1128/AAC.44.6.1524-1529.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  MUTANT STRAINS OF HERPES SIMPLEX DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY.

Authors:  D R DUBBS; S KIT
Journal:  Virology       Date:  1964-04       Impact factor: 3.616

2.  Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir.

Authors:  S Kit; M Sheppard; H Ichimura; S Nusinoff-Lehrman; M N Ellis; J A Fyfe; H Otsuka
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

3.  Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide.

Authors:  D Graham; B A Larder; M M Inglis
Journal:  J Gen Virol       Date:  1986-04       Impact factor: 3.891

4.  Studies on the biochemical basis of spontaneous mutation. I. A comparison of the deoxyribonucleic acid polymerases of mutator, antimutator, and wild type strains of bacteriophage T4.

Authors:  N Muzyczka; R L Poland; M J Bessman
Journal:  J Biol Chem       Date:  1972-11-25       Impact factor: 5.157

5.  Evidence for control of herpes simplex virus mutagenesis by the viral DNA polymerase.

Authors:  J D Hall; R E Almy
Journal:  Virology       Date:  1982-01-30       Impact factor: 3.616

6.  Generation of genetic diversity in herpes simplex virus: an antimutator phenotype maps to the DNA polymerase locus.

Authors:  J D Hall; D M Coen; B L Fisher; M Weisslitz; S Randall; R E Almy; P T Gelep; P A Schaffer
Journal:  Virology       Date:  1984-01-15       Impact factor: 3.616

7.  Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus after in vivo complementation.

Authors:  R B Tenser; W A Edris
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

8.  Properties of herpes simplex virus DNA polymerase and characterization of its associated exonuclease activity.

Authors:  K W Knopf
Journal:  Eur J Biochem       Date:  1979-07

9.  Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates.

Authors:  D S Parris; J E Harrington
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

10.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture.

Authors:  M R Boyd; T H Bacon; D Sutton; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

View more
  19 in total

Review 1.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Effect of dimeric netropsin analogue 15Lys-bis-Nt and acyclovir on the reproduction of herpes simplex virus type 1. The search for variants of herpes virus with drug resistance to 15Lys-bis-Nt and acyclovir.

Authors:  V L Andronova; S L Grokhovsky; A N Surovaya; G V Gursky; G A Galegov
Journal:  Dokl Biochem Biophys       Date:  2015-03-13       Impact factor: 0.788

3.  Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates.

Authors:  Y K Shin; G Y Cai; A Weinberg; J J Leary; M J Levin
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

4.  Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir.

Authors:  R T Sarisky; M R Quail; P E Clark; T T Nguyen; W S Halsey; R J Wittrock; J O'Leary Bartus; M M Van Horn; G M Sathe; S Van Horn; M D Kelly; T H Bacon; J J Leary
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.

Authors:  Sonia Burrel; Claire Deback; Henri Agut; David Boutolleau
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

6.  Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir.

Authors:  Tatsuo Suzutani; Ken Ishioka; Erik De Clercq; Kei Ishibashi; Hisatoshi Kaneko; Toshihiko Kira; Koh-Ichi Hashimoto; Masahiro Ogasawara; Katsuki Ohtani; Nobutaka Wakamiya; Masayuki Saijo
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

7.  Longitudinal Characterization of Herpes Simplex Virus (HSV) Isolates Acquired From Different Sites in an Immune-Compromised Child: A New HSV Thymidine Kinase Mutation Associated With Resistance.

Authors:  Andrew H Karaba; Laura K Cohen; Taly Glaubach; Sarah J Kopp; Jennifer L Reichek; Hawke H Yoon; Xiaotian T Zheng; William J Muller
Journal:  J Pediatric Infect Dis Soc       Date:  2012-05-03       Impact factor: 3.164

8.  Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.

Authors:  Sunwen Chou; Gail I Marousek
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

9.  Penciclovir susceptibilities of herpes simplex virus isolates from patients using penciclovir cream for treatment of recurrent herpes labialis.

Authors:  Robert T Sarisky; Teresa Bacon; Ron Boon; Leslie Locke; Tammy T Nguyen; Jeffry Leary; Klaus Esser; Robin Saltzman
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

Review 10.  Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.

Authors:  Teresa H Bacon; Myron J Levin; Jeffry J Leary; Robert T Sarisky; David Sutton
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.